PET/CT Diagnostik des Prostatakarzinoms mit Bombesinanaloga

Zusammenfassung

Humane Prostatakarzinome exprimieren häufig den Gastrin-Releasing Peptide receptor (GRPr), der auch als Bombesin Typ 2 Rezeptor bekannt ist. In normalem und hyperplastischem Prostatagewebe ist die Binding von GRPr-Liganden hingegen niedrig. Mit Radiometallen markierte GRPr-Antagonisten zeigten im Modell sowohl eine hohe Aufnahme in GRPr-exprimierenden Tumoren, als auch eine schnelle Elimination aus dem Plasma/Normalgewebe. Diese vielversprechenden Charakteristika wurden in klinischen Studien bestätigt, die auch erste Daten zur Sensitivität von GRPr PET/CT zum Nachweis von primären und metastatierten Prostatakarzinomen erhoben. Diese Arbeit gibt eine kurze Übersicht über die Entwicklung von GRPr-basierten Liganden zur Diagnostik (und zur potentiellen Radionuklidtherapie) von Prostatakarzinomen.

Abstract

Human prostate cancers frequently express the gastrin releasing peptide receptor (GRPr), also known as Bombesin type 2receptor. In contrast, expression levels of GRPr are low in normal and hyperplastic prostate tissue. Metabolically stable GRPr antagonists, labeled with radiometals have shown high tumor uptake in preclinical models of prostate cancer. Furthermore, these ligands demonstrated rapid clearance from normal tissues. Clinical studies have confirmed this favorable biodistribution of GRPr antagonists in patients. These studies have also provided first data on the sensitivity of GRPr PET for detection of primary and metastatic prostate cancer. This review provides a brief overview on the clinical development of GRPr ligands for PET imaging (and potentially also for radionuclide therapy) of prostate cancer.

Schlüsselwörter

PET/CT - Bildgebung - Diagnostik - Bombesinanaloga - Prostatakarzinom

Key words

PET/CT - imaging - diagnostics - bombesinanaloga - prostate cancer

• Literatur

• 1 Abiraj K, Mansi R, Tamma ML et al. Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors. J Nucl Med. 2011; 52: 1970-1978 PubMed PMID: 22080443
• 2 Ambrosini V, Fani M, Fanti S et al. Radiopeptide imaging and therapy in Europe. J Nucl Med 2011; 52 (Suppl. 02) 42S-55S PubMed PMID: 22144555
• 3 Ananias HJ, de Jong IJ, Dierckx RA et al. Nuclear imaging of prostate cancer with gastrin-releasing-peptide-receptor targeted radiopharmaceuticals. Curr Pharm Des 2008; 14: 3033-3047 PubMed PMID: 18991717
• 4 Bodei L, Ferrari M, Nunn A et al. 177Lu-AMBA Bombesin analogue in hormone refractory prostate cancer patients: a phase I escalation study with single-cycle administrations [abstract]. Eur J Nucl Med Mol Imaging 2007; 34 (Suppl. 02) S221
• 5 Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 1117-1123 Epub 2010/02/04 PubMed PMID: 20124165; PubMed Central PMCID: PMC2834465
• 6 Cooperberg MR, Lubeck DP, Meng MV et al. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004; 22: 2141-2149 PubMed PMID: 15169800
• 7 de Visser M, van Weerden WM, de Ridder CM et al. Androgen-dependent expression of the gastrin-releasing peptide receptor in human prostate tumor xenografts. J Nucl Med 2007; 48: 88-93 PubMed PMID: 17204703
• 8 Dumont RA, Tamma M, Braun F et al. Targeted radiotherapy of prostate cancer with a gastrin-releasing Peptide receptor antagonist is effective as monotherapy and in combination with rapamycin. J Nucl Med 2013; 54: 762-769 PubMed PMID: 23492884
• 9 Eggener S, Salomon G, Scardino PT et al. Focal therapy for prostate cancer: possibilities and limitations. Eur Urol 2010; 58: 57-64 PubMed PMID: 20378241
• 10 Fesseha T, Sakr W, Grignon D et al. Prognostic implications of a positive apical margin in radical prostatectomy specimens. The Journal of urology 1997; 158: 2176-2179 Epub 1997/11/20. PubMed PMID: 9366338
• 11 Fournier P, Dumulon-Perreault V, Ait-Mohand S et al. Novel radiolabeled peptides for breast and prostate tumor PET imaging: (64)Cu/and (68)Ga/NOTA-PEG-[D-Tyr(6),betaAla(11),Thi(13),Nle(14)]BBN(6-14). Bioconjug Chem 2012; 23: 1687-1693 PubMed PMID: 2277048
• 12 Garrison JC, Rold TL, Sieckman GL et al. In vivo evaluation and small-animal PET/CT of a prostate cancer mouse model using 64Cu bombesin analogs: side-by-side comparison of the CB-TE2A and DOTA chelation systems. J Nucl Med 2007; 48: 1327-1337 PubMed PMID: 17631556
• 13 Hoffman TJ, Gali H, Smith CJ et al. Novel series of 111In-labeled bombesin analogs as potential radiopharmaceuticals for specific targeting of gastrin-releasing peptide receptors expressed on human prostate cancer cells. J Nucl Med. 2003; 44: 823-831 PubMed PMID: 12732685
• 14 Jensen RT, Battey JF, Spindel ER et al. International Union of Pharmacology. LXVIII. Mammalian bombesin receptors: nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacological reviews 2008; 60: 1-42 Epub 2007/12/07 PubMed PMID: 18055507; PubMed Central PMCID: PMC2517428
• 15 Kahkonen E, Jambor I, Kemppainen J et al. In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin Cancer Res. 2013; 19: 5434-5443 Epub 2013/08/13 PubMed PMID: 23935037
• 16 Kasivisvanathan V, Emberton M, Ahmed HU. Focal Therapy for Prostate Cancer: Rationale and Treatment Opportunities. Clin Oncol (R Coll Radiol) 2013; PubMed PMID: 23759249
• 17 Korner M, Waser B, Rehmann R et al. Early over-expression of GRP receptors in prostatic carcinogenesis. Prostate. 2014; 74: 217-224 Epub 2013/10/24 PubMed PMID: 24150752
• 18 Mansi R, Fleischmann A, Macke HR et al. Targeting GRPR in urological cancers – from basic research to clinical application. Nature reviews Urology 2013; 10: 235-244 PubMed PMID: 23507930
• 19 Mansi R, Wang X, Forrer F et al. Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 2011; 38: 97-107 PubMed PMID: 20717822
• 20 Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999; 59: 1152-1159 PubMed PMID: 10070977
• 21 Nanda PK, Wienhoff BE, Rold TL et al. Positron-emission tomography (PET) imaging agents for diagnosis of human prostate cancer: agonist vs. antagonist ligands. In Vivo 2012; 26: 583-592 PubMed PMID: 22773572
• 22 Paulo P, Ribeiro FR, Santos J et al. Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. Neoplasia 2012; 14: 600-611 PubMed PMID: 22904677
• 23 Rogers BE, Bigott HM, McCarthy DW et al. MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjug Chem 2003; 14: 756-763 PubMed PMID: 12862428
• 24 Russell PJ, Kingsley E. Human prostate cancer cell lines. In: Russell PJ, Jackson P, Kingsley E. eds. Methods in Molecular Medicine Prostate Cancer Methods and Protocols. Totowa, NJ: Humana Press; 2003: 21-39
• 25 Safavy A, Khazaeli MB, Qin H et al. Synthesis of bombesin analogues for radiolabeling with rhenium-188. Cancer 1997; 80 (12 Suppl) 2354-2359 PubMed PMID: 9406683
• 26 Sah BR, Burger IA, Schibli R et al. Dosimetry and First Clinical Evaluation of the New 18F-Radiolabeled Bombesin Analogue BAY 864367 in Patients with Prostate Cancer. J Nucl Med 2015; 56: 372-378 PubMed PMID: 25678494
• 27 Schroeder RP, de Visser M, van Weerden WM et al. Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts. Int J Cancer 2010; 126: 2826-2834 PubMed PMID: 19876914
• 28 Schroeder RP, Muller C, Reneman S et al. A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues. Eur J Nucl Med Mol Imaging 2010; 37: 1386-1396 PubMed PMID: 20182713
• 29 Schwartsmann G, DiLeone LP, Horowitz M et al. A phase I trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Investigational new drugs 2006; 24: 403-412 PubMed PMID: 16505950
• 30 Siegel R, Ma J, Zou Z et al. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29 Epub 2014/01/09 PubMed PMID: 24399786
• 31 Van de Wiele C, Dumont F, Vanden Broecke R et al. Technetium-99 m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med 2000; 27: 1694-1699 PubMed PMID: 11105826
• 32 Wieser G, Mansi R, Grosu AL et al. Positron Emission Tomography (PET) Imaging of Prostate Cancer with a Gastrin Releasing Peptide Receptor Antagonist – from Mice to Men. Theranostics 2014; 4: 4124-419 PubMed PMID: 24578724
• 33 Wieser G, Popp I, Mansi R et al. GRPR antagonist 68Ga-RM2 as PET tracer for imaging prostate cancer: Initial experiences. J Nucl Med 2014; 55 (Suppl. 01) 17P
• 34 Yang JC, Ok JH, Busby JE et al. Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res 2009; 69: 151-160 PubMed PMID: 19117998
• 35 Yossepowitch O, Bjartell A, Eastham JA et al. Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol 2009; 55: 87-99 Epub 2008/10/08 PubMed PMID: 18838211
• 36 Zhang X, Cai W, Cao F et al. 18 F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med 2006; 47: 492-501 PubMed PMID: 16513619